PMID- 38143016
OWN - NLM
STAT- Publisher
LR  - 20240119
IS  - 1778-7254 (Electronic)
IS  - 1297-319X (Linking)
VI  - 91
IP  - 3
DP  - 2023 Dec 22
TI  - Glucocorticoid treatment and clinical outcomes in patients with polymyalgia 
      rheumatica: A cohort study using routinely collected health data.
PG  - 105680
LID - S1297-319X(23)00159-8 [pii]
LID - 10.1016/j.jbspin.2023.105680 [doi]
AB  - OBJECTIVE: We aimed to describe the following in patients with polymyalgia 
      rheumatica (PMR): (1) real-world glucocorticoid (GC) therapy, (2) improvement in 
      inflammatory parameters associated with disease activity (C-reactive protein 
      [CRP] level and erythrocyte sedimentation rate [ESR]), and (3) incidence of 
      GC-related adverse events (AEs). METHODS: A cohort study was conducted using a 
      Japanese electronic medical records database. We included newly diagnosed PMR 
      patients aged>/=50years with baseline CRP levels>/=10mg/L and/or ESR>30mm/h and an 
      initial GC dose of>/=5mg/day. The outcomes were GC dose, inflammatory parameters, 
      and GC-related AEs. RESULTS: A total of 373 PMR patients (mean age, 77.3 years) 
      were analyzed. The median initial GC dose was 15.0mg/day, which gradually 
      decreased to 3.5mg/day by week 52. The median cumulative GC dose at week 52 was 
      2455.0mg. The median CRP level on day 0 was 64.3mg/L, which decreased during 
      weeks 4-52 (1.4-3.2mg/L). At week 52, 39.0% of patients had a CRP level>3.0mg/L. 
      The cumulative incidence of GC-related AEs at week 52 was 49.0% for osteoporosis, 
      30.2% for diabetes, 14.9% for hypertension, 12.2% for peptic ulcer, 11.3% for 
      dyslipidemia, 2.9% for glaucoma, and 4.3% for serious infection. The incidence of 
      osteoporosis and diabetes increased with the GC dose. CONCLUSION: The incidence 
      of GC-related AEs was associated with the GC dose in PMR patients. Further 
      research is required to identify treatment strategies that can effectively 
      control PMR disease activity while minimizing GC use.
CI  - Copyright (c) 2023 The Author(s). Published by Elsevier Masson SAS.. All rights 
      reserved.
FAU - Tanaka, Yoshiya
AU  - Tanaka Y
AD  - First Department of Internal Medicine, School of Medicine, University of 
      Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahatanishi-ku, 
      Kitakyushu, Fukuoka, 807-8555 Japan.
FAU - Tanaka, Shinichi
AU  - Tanaka S
AD  - Medical Affairs Department, Asahi Kasei Pharma Corporation, 1-1-2 Yurakucho, 
      Chiyoda-ku, Tokyo, 100-0006 Japan.
FAU - Fukasawa, Toshiki
AU  - Fukasawa T
AD  - Research and Analytics Department, Real World Data Co., Ltd., Shiseido Kyoto 
      Bld.4F, 480, Aburanokojidori Kizuyabashi-sagaru Kitafudondocho Shimogyo-ku 
      kyoto-shi, Kyoto, 600-8233 Japan.
FAU - Inokuchi, Shoichiro
AU  - Inokuchi S
AD  - Research and Analytics Department, Real World Data Co., Ltd., Shiseido Kyoto 
      Bld.4F, 480, Aburanokojidori Kizuyabashi-sagaru Kitafudondocho Shimogyo-ku 
      kyoto-shi, Kyoto, 600-8233 Japan.
FAU - Uenaka, Hidetoshi
AU  - Uenaka H
AD  - Research and Analytics Department, Real World Data Co., Ltd., Shiseido Kyoto 
      Bld.4F, 480, Aburanokojidori Kizuyabashi-sagaru Kitafudondocho Shimogyo-ku 
      kyoto-shi, Kyoto, 600-8233 Japan.
FAU - Kimura, Takeshi
AU  - Kimura T
AD  - Research and Analytics Department, Real World Data Co., Ltd., Shiseido Kyoto 
      Bld.4F, 480, Aburanokojidori Kizuyabashi-sagaru Kitafudondocho Shimogyo-ku 
      kyoto-shi, Kyoto, 600-8233 Japan.
FAU - Takahashi, Toshiya
AU  - Takahashi T
AD  - Medical Affairs Department, Asahi Kasei Pharma Corporation, 1-1-2 Yurakucho, 
      Chiyoda-ku, Tokyo, 100-0006 Japan; Specialty Care Medical, Sanofi K.K., 3-20-2, 
      Nishi-Shinjuku, Shinjuku-ku, Tokyo, 163-1488 Japan.
FAU - Kato, Naoto
AU  - Kato N
AD  - Medical Affairs Department, Asahi Kasei Pharma Corporation, 1-1-2 Yurakucho, 
      Chiyoda-ku, Tokyo, 100-0006 Japan. Electronic address: 
      kato.nv@om.asahi-kasei.co.jp.
LA  - eng
PT  - Journal Article
DEP - 20231222
PL  - France
TA  - Joint Bone Spine
JT  - Joint bone spine
JID - 100938016
SB  - IM
OTO - NOTNLM
OT  - Adverse events
OT  - Glucocorticoids
OT  - Polymyalgia rheumatica
OT  - Real-world data
OT  - Treatment
EDAT- 2023/12/25 00:42
MHDA- 2023/12/25 00:42
CRDT- 2023/12/24 19:32
PHST- 2023/07/04 00:00 [received]
PHST- 2023/11/15 00:00 [revised]
PHST- 2023/12/19 00:00 [accepted]
PHST- 2023/12/25 00:42 [pubmed]
PHST- 2023/12/25 00:42 [medline]
PHST- 2023/12/24 19:32 [entrez]
AID - S1297-319X(23)00159-8 [pii]
AID - 10.1016/j.jbspin.2023.105680 [doi]
PST - aheadofprint
SO  - Joint Bone Spine. 2023 Dec 22;91(3):105680. doi: 10.1016/j.jbspin.2023.105680.